🔴 Moleculin Biotech is trading 5.6% down today in pre-market without a clear negative catalyst

Moleculin Biotech is trading 5.6% down at $0.65 in pre-market, with no clear negative company-specific catalyst identified.

• Shares gained 14.78% to $0.69 on August 27, 2026.
• The company highlighted positive interim MIRACLE trial results, including complete-remission rates at least three times higher than the control arm, during its August 27 Virtual Investor presentation.
• That favorable news does not directly explain the current decline.